Tirzepatide

The Uncomfortable Truth About Ozempic

Kurzgesagt – In a Nutshell

GLP-1/GIP dual agonist (tirzepatide); described in the video as a powerful weight-loss/diabetes drug (brand mention in transcript as tzepatite).

The Ozempic Expert: Ozempic Transforms Your Gut Microbiome! People Are Being Overdosed On Ozempic!

The Diary Of A CEO

Dr. Mehmet Oz on Fixing American Healthcare + Fraud | Live from Davos

All-In Podcast

337- Insulin resistance masterclass: The full body impact of metabolic dysfunction, treatment & more

Peter Attia MD

Peptide & Hormone Therapies for Health, Performance & Longevity | Dr. Craig Koniver

Andrew Huberman

Referred to as semaglutide version 2.0, primarily used for type 2 diabetics and for weight loss. Dr. Koniver uses compounded micro-dosages to mitigate muscle loss.

252 ‒ Latest insights on Alzheimer’s disease, cancer, exercise, nutrition, and fasting

Peter Attia MD

A GLP-1 agonist, mentioned as a drug for weight loss, with concerns about its use for minor weight loss and potential for muscle wasting if protein intake is not maintained.

Dave Ricks, CEO of Eli Lilly | The All-In Interview

All-In Podcast

The active drug in Mounjaro and Zepbound, a dual agonist for GLP-1 and GIP receptors, leading to substantial weight loss.

The Science of Hunger & Medications to Combat Obesity | Dr. Zachary Knight

Andrew Huberman

A GLP-1/GIP dual agonist drug, marketed as Mounjaro for diabetes and Zepbound for obesity, which is more effective than semaglutide with fewer side effects.

Pros and cons of GLP-1 weight loss drugs and metformin as a geroprotective agent [AMA 45 sneak peek]

Peter Attia MD

A co-agonist drug that acts on both GLP-1 and GIP receptors, known by the brand name Mounjaro, showing promising results for weight loss.

230 ‒ Cardiovascular disease in women: prevention, risk factors, lipids, and more

Peter Attia MD

A new dual agonist (GIP and GLP-1 receptor agonist) approved for diabetes with dramatic weight loss effects (up to 50 pounds), but cardiovascular outcome trials for diabetes are ongoing, and not yet FDA approved for weight management.